Comparison of the prognosis and outcome of heart failure with reduced ejection fraction patients treated with sacubitril/valsartan according to age

被引：11

作者：

Abumayyaleh, Mohammad ^{[1
,2
]}

El-Battrawy, Ibrahim ^{[1
,2
]}

Kummer, Marvin ^{[1
,2
]}

Pilsinger, Christina ^{[1
]}

Sattler, Katherine ^{[1
]}

Kuschyk, Juergen ^{[1
]}

Aweimer, Assem ^{[3
]}

Muegge, Andreas ^{[3
]}

Borggrefe, Martin ^{[1
,2
]}

Akin, Ibrahim ^{[1
,2
]}

机构：

[1] Heidelberg Univ, Univ Med Ctr Mannheim, Dept Med 1, Mannheim, Germany

[2] DZHK German Ctr Cardiovasc Res, Partner Site, Mannheim, Germany

[3] Ruhr Univ Bochum, Bergmannsheil Univ Hosp, Dept Cardiol & Angiol, Bochum, Germany

来源：

FUTURE CARDIOLOGY | 2021年 / 17卷 / 06期

关键词：

adult patients; age; mortality rate; older patients; sacubitril/valsartan; ANGIOTENSIN-NEPRILYSIN INHIBITION; NEUTRAL ENDOPEPTIDASE; NATRIURETIC PEPTIDES; LCZ696; MORTALITY; CONGESTION; MORBIDITY; ENALAPRIL; INSIGHTS; HISTORY;

D O I：

10.2217/fca-2020-0213

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The treatment with sacubitril/valsartan in patients suffering from chronic heart failure with reduced ejection fraction increases left ventricular ejection fraction and decreases the risk of sudden cardiac death. We conducted a retrospective analysis regarding the impact of age differences on the treatment outcome of sacubitril/valsartan in patients with chronic heart failure with reduced ejection fraction. Patients were defined as adults if <= 65 years (n = 51) and older if >65 years of age (n = 76). The incidence of ventricular arrhythmias at 1-year follow-up was comparable in both groups (30.8 vs 26.5%; p = 0.71). The mortality rate in adult patients is significantly lower as compared with older patients (2 vs 14.5%; log-rank = 0.04). Older patients may suffer remarkably more side effects than adult patients (21.1 vs 11.8%; p = 0.03).

引用

页码：1131 / 1142

页数：12

共 45 条

[1] Current evidence of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction [J].

Abumayyaleh, Mohammad ;

El-Battrawy, Ibrahim ;

Behnes, Michael ;

Borggrefe, Martin ;

Akin, Ibrahim .

FUTURE CARDIOLOGY, 2020, 16 (04) :227-236

[2] Medication Management of Chronic Heart Failure in Older Adults [J].

Alagiakrishnan, Kannayiram ;

Banach, Maciej ;

Jones, Linda G. ;

Ahmed, Ali ;

Aronow, Wilbert S. .

DRUGS & AGING, 2013, 30 (10) :765-782

[3]

Almufleh A, 2017, AM J CARDIOVASC DIS, V7, P108

[4] Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists [J].

Ambrosy, Andrew P. ;

Braunwald, Eugene ;

Morrow, David A. ;

DeVore, Adam D. ;

McCague, Kevin ;

Meng, Xiangyi ;

Duffy, Carol I. ;

Rocha, Ricardo ;

Velazquez, Eric J. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (09) :1034-1048

[5] Long-term survival of cancer patients compared to heart failure and stroke: A systematic review [J].

Askoxylakis, Vasileios ;

Thieke, Christian ;

Pleger, Sven T. ;

Most, Patrick ;

Tanner, Judith ;

Lindel, Katja ;

Katus, Hugo A. ;

Debus, Juergen ;

Bischof, Marc .

BMC CANCER, 2010, 10

[6] Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation [J].

Chang, Hung-Yu ;

Feng, An-Ning ;

Fong, Man-Cai ;

Hsueh, Chao-Wen ;

Lai, Wei-Tsung ;

Huang, Kuan-Chih ;

Chong, Eric ;

Chen, Chi-Nan ;

Chang, Hung-Chuan ;

Yin, Wei-Hsian .

JOURNAL OF CARDIOLOGY, 2019, 74 (3-4) :372-380

[7] Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry [J].

Chioncel, Ovidiu ;

Mebazaa, Alexandre ;

Maggioni, Aldo P. ;

Harjola, Veli-Pekka ;

Rosano, Giuseppe ;

Laroche, Cecile ;

Piepoli, Massimo F. ;

Crespo-Leiro, Maria G. ;

Lainscak, Mitja ;

Ponikowski, Piotr ;

Filippatos, Gerasimos ;

Ruschitzka, Frank ;

Seferovic, Petar ;

Coats, Andrew J. S. ;

Lund, Lars H. .

EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 (11) :1338-1352

[8] Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure [J].

Damman, Kevin ;

Gori, Mauro ;

Claggett, Brian ;

Jhund, Pardeep S. ;

Senni, Michele ;

Lefkowitz, Martin P. ;

Prescott, Margaret F. ;

Shi, Victor C. ;

Rouleau, Jean L. ;

Swedberg, Karl ;

Zile, Michael R. ;

Packer, Milton ;

Desai, Akshay S. ;

Solomon, Scott D. ;

McMurray, John J., V .

JACC-HEART FAILURE, 2018, 6 (06) :489-498

[9] Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices [J].

de Diego, Carlos ;

Gonzalez-Torres, Luis ;

Maria Nunez, Jose ;

Centurion Inda, Raul ;

Martin-Langerwerf, David A. ;

Sangio, Antonio D. ;

Chochowski, Piotr ;

Casasnovas, Pilar ;

Blazquez, Julio C. ;

Almendral, Jesus .

HEART RHYTHM, 2018, 15 (03) :395-402

[10] Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients [J].

Desai, Akshay S. ;

McMurray, John J. V. ;

Packer, Milton ;

Swedberg, Karl ;

Rouleau, Jean L. ;

Chen, Fabian ;

Gong, Jianjian ;

Rizkala, Adel R. ;

Brahimi, Abdel ;

Claggett, Brian ;

Finn, Peter V. ;

Hartley, Loren Howard ;

Liu, Jiankang ;

Lefkowitz, Martin ;

Shi, Victor ;

Zile, Michael R. ;

Solomon, Scott D. .

EUROPEAN HEART JOURNAL, 2015, 36 (30) :1990-1997

← 1 2 3 4 5 →